Just One in Three Portuguese Family Doctors Feels Fully Prepared to Insert an IUD or Implant — A 220-GP Survey Surfaces a Procedural Gap in SNS Long-Acting Contraception

A new Portuguese survey of 220 family doctors, reported by Público on 26 April 2026, finds that only 31.8% of respondents feel completamente preparados — "completely prepared" — to place long-acting reversible contraceptives in their consultation rooms. The methods in question are intrauterine devices, intrauterine systems and subdermal implants — the three contraceptives the World Health Organization classes as first-line for adult women, and the three that Portugal's Direção-Geral da Saúde has been steering primary care toward for a decade.

The Headline Number, in Context

Two-thirds of Portuguese family doctors run family-planning consultations. Almost all of them prescribe combined oral contraceptives. Far fewer feel confident moving a patient onto a method that requires a clinical procedure — a four-minute insertion of a copper or hormonal IUD, or a five-minute placement of an etonogestrel implant under local anaesthetic. The survey's central finding is the gap between that prescribing volume and the procedural confidence behind it.

The authors propose simulation-based practical training and stronger collaboration between centros de saúde and the gynaecology services of public hospitals as the route to closing the gap. The recommendation is not a question of medical knowledge — Portuguese GPs are well-versed in the indications, contraindications and follow-up protocols. It is procedural fluency: the body memory of doing the insertion, often, on real patients, with a confident operator nearby.

Why It Matters for the SNS

Long-acting reversible contraception (LARC) is the most cost-effective modality the National Health Service offers in primary-care women's health. A single insertion covers three to ten years of cover, removes the daily-pill compliance failure mode, and shifts a measurable share of unintended-pregnancy risk out of the obstetric system entirely. The SNS pays for the device and the consultation — the user-side cost is zero.

That economic logic only works if the GP at the centro de saúde can place the device the patient is being counselled to choose. If she has to be referred to a hospital gynaecology consultation, the median wait pushes past six months in several ARS regions, by which point the user is back on a pill that does not fit her life. That is the queue the survey is implicitly mapping.

The European Context

Portugal sits at the top of European rankings for contraceptive coverage — the most recent comparative data place it second in Europe for use of contraception among young people, with around 94% of sexually active women using some method. The country's reproductive-health architecture, built up since the 2007 abortion-law reform, is dense by EU standards. The weakness is not access on paper — it is procedural depth in primary care, particularly outside Lisboa-Vale do Tejo and Greater Porto.

What Closes the Gap

Three things, in sequence, would shift the 31.8% number. First, a structured Ordem dos Médicos competency module for family medicine that includes hands-on LARC insertion supervised by a gynaecologist — the kind of pairing the new survey's authors are explicitly asking for. Second, ring-fenced clinic time at centros de saúde where IUD and implant placements are scheduled in advance, instead of squeezed into 15-minute family-planning slots. Third, a pricing or staffing signal from the Ministry that tells ACES managers this is what their family-planning indicators will be measured on.

None of those are policy headlines. All three would do more for SNS reproductive-care quality than another national strategy document.

Sources: Público ("Contracepção: médicos de família pouco confiantes a colocar dispositivos e implantes", Ana Maia, 26 April 2026); Direção-Geral da Saúde family-planning guidelines; Observador (Portugal European contraception ranking, May 2025); WHO family-planning guidance on first-line LARCs.

See also our coverage of free walk-in HIV and hepatitis screening at AML pharmacies.